This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Original Article -
Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism
Yong Wang1, Chen Shao2, Chang-Hong Shi3, Lei Zhang4, Hong-Hong Yue5, Peng-Fei Wang2, Bo Yang2, Yun-Tao Zhang2, Fan Liu1, Wei-Jun Qin2, He Wang2, Guo-Xing Shao2
1Department of Urology, Tangdu Hospital,
2Department of Urology, 3Department of Microbiology,
4Department of Epidemiology,
5Department of Nephrology, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, Shaanxi, China
Abstract
Aim: To explore the effect of androgen receptor (AR) on the expression of the cell cycle-related genes, such as
CDKN1A and BTG1, in prostate cancer cell line LNCaP.
Methods: After AR antagonist flutamide treatment and
confirmation of its effect by phase contrast microscope and flow cytometry, the differential expression of the cell
cycle-related genes was analyzed by a cDNA microarray. The flutamide treated cells were set as the experimental
group and the LNCaP cells as the control. We labeled cDNA probes of the experimental group and control group with
Cy5 and Cy3 dyes, respectively, through reverse transcription. Then we hybridized the cDNA probes with cDNA
microarrays, which contained 8 126 unique human cDNA sequences and the chip was scanned to get the fluorescent
values of Cy5 and Cy3 on each spot. After primary analysis, reverse transcription polymerase chain reaction
(RT-PCR) tests were carried out to confirm the results of the chips.
Results:After AR antagonist flutamide treatment,
three hundred and twenty-six genes
(3.93%) expressed differentially, 97 down-regulated and 219 up-regulated.
Among them, eight up-regulated genes might be cell cycle-related, namely
CDC10, NRAS, BTG1,
Wee1, CLK3, DKFZP564A122,
CDKN1A and BTG2. The CDKN1A and
BTG1 gene mRNA expression was confirmed to be higher
in the experimental group by RT-PCR, while
p53 mRNA expression had no significant changes.
Conclusion: Flutamide treatment might up-regulate
CDKN1A and BTG1 expression in prostate cancer cells. The protein expressions of
CDKN1A and BTG1 play an important role in inhibiting the proliferation of cancer cells.
CDKN1A has a great impact on the cell cycle of prostate cancer cells and may play a role in the cancer cells in a
p53-independent pathway. The prostate cancer cells might affect the cell cycle-related genes by activating AR and thus break the cell cycle control.
(Asian J Androl 2005 Dec; 7: 375-380)
Keywords: prostate cancer; LNCaP; p21; androgen receptor; CDKN1A; BTG1; cell cycle genes; flutamide
Correspondence to: Dr Chen Shao, Department of Urology, Xijing
Hospital, Fourth Military Medical University, Xi'an 710032,
Shaanxi, China.
Tel/Fax: +86-29-8337-5321
E-mail: shaochen@fmmu.edu.cn
Received 2004-06-30 Accepted 2005-01-11
DOI: 10.1111/j.1745-7262.2005.00031.x
1 Introduction
Prostate cancer is a worldwide disease. The
incidence of prostate cancer in Europe was 103.5 cases per
100 000 men in the year 2000 [1]. In USA, the
incidence of this disease increased steadily between 1981
and 1989, with a steep increase in the early 1990s. In
1996, 317 000 new cases of prostate cancer have been
detected, while 41 400 patients died of this disease in the
USA [2]. In China, some well-developed areas such as
Shanghai also have seen a dramatic increase in the
incidence of prostate cancer due to changes of lifestyles and
dietary patterns [3].
Clinical therapy of prostate cancer involves radical
prostatectomy followed by adjuvant hormonotherapy or
chemotherapy. Administration of antiandrogens provides
only partial remission because prostate cancer cells
acquire a hormone-independent phenotype and the disease
relapses within a few years. Therefore, the
development of androgen independency of prostate cancer is the main
cause of therapeutic failure. Nevertheless, the
underlying molecular mechanisms involved in this situation were
not clearly understood [4].
In this study, we used the well-characterized,
hormone-sensitive human prostate cancer cell line LNCaP
to identify early mechanisms involved in the acquisition
of hormone independence.
2 Materials and methods
2.1 Materials
LNCaP cells were cultured in RPMI-1640 medium
sup-plemented with 10% fetal bovine serum
(FBS) (Hyclone Inc., Savannah, USA)[5]. Stock solutions of the
androgen receptor (AR) antagonist flutamide (Sigma Inc., St.
Louis, USA) (10-4 mol/L) were made in absolute ethanol,
while working solutions were further made in
phosphate-buffered saline (PBS) (pH 7.2) [6]. Flutamide was
routinely used at a final concentration of
10-7 mol/L. In the control (non-treated) group, an equal volume of pure
ethanol, dissolved in PBS was used to eliminate any
effect of the vehicle. After 15 days of treatment, with a
change of the medium every 2 days, when the experimental group cells reached
90% confluence, we isolated mRNA and analyzed it after reverse transcription.
Cy3-dCTP and Cy5-dCTP were purchased from Amersham Phamacia Biotech Inc. (Piscataway, NJ, USA)
and Oligotex mRNA Midi Kit from Quigen Inc. (Valencia,
CA, USA). ScanArray 4 000 laser scanner was from GSI
Lomonics (Ottawa, Ontario, Canada). GenePix Pro 3.0
software from Axon Instruments Inc. (Sunnyvale, CA,
USA).
2.2 Methods
2.2.1 Analysis of cell cycle changes
The control cells and cells that had been treated with
flutamide for 15 days were analyzed by microscopy, using
a microscope (Olympus, Tokyo, Japan) provided with a
camera (Olympus, Tokyo, Japan). Additionally, cells
were collected and placed into 6-well plates at a density
of 1 × 105/mL, washed with 0.01 mol/L PBS (pH 7.2),
fixed in 70% ethanol for 18 h, resuspended in PBS
and stained with propidium iodide (100 ìg/mL) for
30 min. Flow cytometer was explored by using blue light
Argon-Ion laser (excitation wavelength, 488 nm; laser
power, 200 mW; ELITE ESP, Beckman-Coulter,
Fuller-ton, CA, USA) and red fluorescence from the PI/DNA
was recorded. Cell cycle analysis was performed using
a DNA-Prep Reagent System, with the following settings:
one cycle analysis, no apoptosis.
2.2.2 Microarray assay
mRNA was extracted by Trizol and purified by
Oli-gotex Midi Kit (Quigen Inc., Valencia, CA, USA)[7].
Microarray analysis was performed by using the Human
Gene Expression CHIP (version H80s, Biostar, Shanghai,
China) containing 8 126 human genes. A fluorescent
probe was synthesized by reverse transcription of
100 ìg of the above mRNA with 50 U AMV reverse transcriptase
(Takara Shuzo, Kyoto, Japan) in the presence of Cy3- or
Cy5-dCTP (Amersham, Arlington Heights, USA). Then
Cy3- and Cy5-labeled probes were prepared and incubated in the cDNA chip at 42 °C for 6 h, washed twice
with 2 × Standard Saline
Citrate(SSC)/0.2% SDS at 60 °C for 30 min and then washed again with the same
buffer for 5 min. Finally, the chip was washed with
0.05 × SSC at room temperature for 10 min and signals were
quantified with the ScanArray 4000 (GSI Lomonics, Ottawa,
Canada) and the Quant Array Software (GSI Lomonics,
Ottawa, Canada). All the Cy3 fluorescent units were
normalized according to the normalized factor [6] and
Cy5 fluorescent intensity was counted as 200 if it was
below 200 fluorescent units. The expression changes of
genes were considered as up-regulated if the Cy5/Cy3
signal ratio was higher than 2.0 and down-regulated if
the ratio was lower than 0.5.
2.2.3 Semi-quantitative RT-PCR
Total RNA was extracted by the Qiagen RNA Isolation Kit (GIBCO Co., New York, USA). For the
first-strand cDNA synthesis, 5 mg/mL of RNA (Takara Co.,
Dalian, China) were used. In each reaction, a 100-mL
solution containing 3 mmol random hexamers,
25 mmol/L Tris-HCl, 37 mmol/LKCl, 1.5
mmol/LMgCl2, 10 mmol/LDTT, 0.25 mmol/L dNTP, 40 units of RNasin, a RNase
inhibitor, 50 U /mL Super Taq DNA polymerase, and 200
units of reverse transcriptase were used. The annealing
mixture was incubated at room temperature for 15 min,
and then incubated in a water bath at 41 °C for 60 min.
The reverse transcriptase enzyme was inactivated by
heating the solution to 95 °C for 5 min. PCR was then
carried out using PCR kit (Perkin-Elmer, Foster City,
CA, USA) and primers. The PCR was performed for 30
cycles consisting of denaturation at 94 °C for 1 min,
annealing at 57 °C for 1 min, and extension at
72 °C for 2 min. The PCR products were analyzed on
1.5% agarose gel. The primers used for PCR were as follow:
CDKN1A sense (5¡¯-GAC ACC ACT GGA GGG TGA
CT-3¡¯), CDKN1A antisense (5¡¯-TAC AGG TCC ACA TGG
TCT TCC-3¡¯); b-actin sense (5¡¯-GAT TGC CTC AGG
ACA TTT CTG-3¡¯), b-actin antisense (5¡¯-GAT TGC TCA
GGA CAT TTC TG-3¡¯) [8]. And another experiment of
KLK3 (its gene product is PSA) expression was also
carried out, with the primers set as follow:
KLK3 sense (5¡¯-AGC GTG ATC TTG CTG GGT CG-3¡¯),
KLK3 antisense (5¡¯-CGT CAT TGG AAA TAA CAT GGA GG-3¡¯). Gene
primers were synthesized by Beijing Oake Company (Beijing, China).
3 Results
3.1 Morphological and cell cycle changes induced by
flutamide
Flutamide treatment of LNCaP cells for 15 days
resulted in dramatic changes of cell morphology (Figures 1,
2). Antiandrogen-treated cells became smaller, while less
mitoses and cell contacts were found. The density of
cells also diminished. The results of flow cytometer
indicated that (71.47 ± 0.96)% of LNCaP cells sustained at
G1 phase after the flutamide treatment while that of
control cells was only (66.87 ± 1.50) % (Table 1).
3.2 The changes of gene expression after flutamide treatment
Detection of RNA purity was assayed by electrophoresis in agarose gels, and absorption spectrometry.
As shown in Figure 3, 18S and 28S bands were clean
and clear, while absorbance measurements revealed
A260/A280 >2.0, indicating that the extracted mRNA was
suitable for cDNA microarray assay.
According to the criteria offered by the chip
manufacturer (Cy5/Cy3*>2.0, up-regulated;
Cy5/Cy3*<0.5, down-regulated), there were 326 genes
(3.93%) which were expressed differentially after the treatment with
flutamide. Ninety-seven genes were up-regulated and
219 were down-regulated (Figure 4). It was very
interesting that there was an increased expression of eight
genes related to cell cycle, namely CDC10,
NRAS, BTG1, Wee1, CLK3,
DKFZP564A122, CDKN1A and BTG2 (Table 2). Especially
CDKN1A and BTG1 who have relatively high Cy3 value. Meanwhile,
p53 and its related genes did not change much after flutamide treatment
(Table 3).
The induction of PSA mRNA may reflect the ability
of AR to stimulate transcription, for the 5¡¯-regulatory
region of the PSA gene contains multiple androgen
responseelements [5]. PSA was obviously down-regulated
(Cy5/Cy3=0.202) in our chip assay, while AR did not change
(Cy5/Cy3=0.65).
3.3 Semi-quantitative RT-PCR confirmation
In the control (non-treated) group, the
CDKN1A expression in the LNCaP cells was merely faintly detected
by RT-PCR. In contrast, in flutamide-treated LNCaP
cells, the expression of this gene product was
significantly up-regulated (Figure 5). In contrast,
KLK3 (PSA) expression was down-regulated (as expected) after
flutamide, indicating an effective blockage of AR by
chronic flutamide treatment (Figure 6).
4 Discussion
AR plays a great role in regulating the proliferation of
both normal and neoplastic prostate cells. The activated
DNA-bound AR homodimer complex recruits several kinds of co-regulatory proteins to stimulate or inhibit
target gene transcription, thus promotes or represses cell
proliferation, apoptosis or angiogenesis [9].
In this study, we found that eight cell cycle-related
genes, namely CDC10, NRAS,
BTG1, Wee1, CLK3,
DKFZP564A122, SLC31A1 and
CDKN1A, were up-regulated in prostate cancer cells after flutamide treatment.
In contrast, p53 and its downstream genes, such as
tumor protein p53-binding protein TOPORS (Gene
alias: TP53BPL), TP53BP1,
PA2, TP53BP2 and p53DINP1, remain unchanged.
CDKN1A is an important cell cycle regulator [10].
Its gene product p21 (waf1/cip1) can inhibit the
proliferation of cancer cells via both p53-dependent and
p53-independent CDK inhibition. In many tumors,
CDKN1A could be activated through the
p53-indpendent pathway[11, 12], in which mitogens as platelet-derived growth
factor (PDGF), fibroblast growth factor (FGF), and
epidermal growth factor (EGF) may function[13]. Choi et al. [12]reported that in prostate cancer cell line PC-3,
the p53-independent pathway to activate
CDKN1A may be related with over-expression of
CDC2 and CDK2. Our results showed that there was no significant change of
p53 gene and its downstreamgenes after flutamide
treatment; we assumed that the high expression of
CDKN1A may occur through a p53-independent
pathway in this experiment. Kokontis et
al.[14] found that androgen may inhibit androgen refractory prostate
cancer cell line LNCaP-104R1 proliferation by a transient
p21 (waf1/cip1) induction and following
p27 (Kip1) induction as a result of a drop in
c-myc expression. However, in our research, we found neither
p27 (Kip1) nor c-myc¡¯s expression changed (data not shown),
suggesting a different pathway in androgen prolific cell line.
Since there have been reports that CDKN1A
expression was associated with tumor progression to
androgen-independent prostate carcinoma [4], we supposed that
p21 may play a key role in molecular events of the initiation
of AIPC because of its anti-apoptotic effect.
Eder et al.[15] found in 2003 that after AR blockage
by antisense oligonucleotide, the expression of
IGFBP2, PIP5KIA, PTOV1 and
S100P changed. However, in this study, we did not find the same kind of results.
The other genes we discovered in this experiment
were also of interest. BTG1, for example, may play a
coordinate role in a general transduction pathway that
was induced in response to DNA damage[16]. BTG1 expression was maximal in the
G0/G1 phases of the cell cycle and
was down-regulated when cells progress throughout
G1[17]. It affected the proliferation by
phosphorylating a putative p34cdc2 kinase site on BTG1,
Ser-159, thus modulated CCR4 expression, and then induced
the formation of hCAF-1/BTG1, which was of great consequence in the signaling events of cell division that lead
to changes in cellular proliferation associated with
cell-cell contact[18]. However, a shortage of correlated
reports hinder further research of this gene on the prostate
cancer cells¡¯ proliferation and cell contact.
In conclusion, we found that eight cell cycle-related
genes may be involved in the process of
flutamide-induced cell growth inhibition, especially
CDKN1A and BTG1. CDKN1A may function on the prostate cancer
cells in a p53-independent mode. The clarification of
exact mechanism of flutamide¡¯s inhibitive effect on
prostate cancer cells is of great importance in clinical
hormone therapy. Designing a new way with
biotechnology to mimic and maximize flutamide¡¯s anti-cancer
effect while avoiding its notorious hepatotoxicity may be
an interesting idea to pursue in the future.
Acknowledgment
We owe our thanks to Professor Jian-Guang Zhou,
the Academy of Military Medical Sciences (Beijing, China),
for providing LNCaP cells. This project was granted by
the National Nature Science Foundation of China (No.
30100185).
References
1. Herranz Amo F, Arias Funez F, Arrizabalaga Moreno M,
Calahorra Fernandez FJ, Carballido Rodriguez J, Diz Rodriguez
R, et al. The prostate cancer in the community of Madrid in
2000 I.- Incidence. Actas Urol Esp 2003; 27: 323-34.
2. Sarma AV, Schottenfeld D. Prostate cancer incidence, mortality,
and survival trends in the United States: 1981-2001. Semin
Urol Oncol 2002; 20: 3-9.
3. Hsing AW, Devesa SS, Jin F, Gao YT. Rising incidence of
prostate cancer in Shanghai, China. Cancer Epidemiol
Biomarkers Prev 1998; 7: 83-4.
4. Feldman BJ, Feldman D. The development of
androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45.
5. Kanaya J, Takashima M, Koh E, Namiki M.
Androgen-independent growth in LNCaP cell lines and steroid uridine
diphosphate-glucuronosyltransferase expression. Asian J Androl
2003; 5: 9-13.
6. Kumar VL, Majumder PK, Kumar V. In
vivo modulation of androgen receptor by androgens. Asian J Androl 2002; 4:
229-31.
7. Kappler-Hanno K, Kirchhoff C. Rodent epididymal cDNAs
identified by sequence homology to human and canine
counterparts. Asian J Androl 2003; 5: 277-86.
8. Kuwano K, Hagimoto N, Nomoto Y, Kawasaki M, Kunitake
R, Fujita M, et al. P53 and
p21 (Waf1/Cip1) mRNA expression associated with DNA damage and repair in acute immune
complex alveolitis in mice. Lab Invest 1997; 76: 161-9.
9. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor
coregulators: cellular and molecular biology. Endocr Rev 1999;
20: 321-44.
10. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The
p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1
cyclin-dependent kinases. Cell 1993; 75: 805-16.
11. Zeng YX, el-Deiry WS. Regulation of
p21WAF1/CIP1 expression by p53-independent pathways. Oncogene 1996; 12:
1557-64.
12. Choi YH, Lee WH, Park KY, Zhang L. p53-independent
induction of p21 (WAF1/CIP1), reduction of cyclin B1 and
G2/M arrest by the isoflavone genistein in human prostate
carcinoma cells. Jpn J Cancer Res 2000; 91: 164-73.
13. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D.
Induction of WAF1/CIP1 by a p53-independent pathway.
Cancer Res 1994; 54: 3391-5.
14. Kokontis JM, Hay N, Liao S. Progression of LNCaP prostate
tumor cells during androgen deprivation:
hormone-independent growth, repression of proliferation by androgen, and role
for p27Kip1 in androgen-induced cell cycle arrest. Mol
Endocrinol 1998; 12: 941-53.
15. Eder IE, Haag P, Basik M, Mousses S, Bektic J, Bartsch G,
et al. Gene expression changes following androgen receptor
elimination in LNCaP prostate cancer cells. Mol Carcinog 2003;
37: 181-91.
16. Rouault JP, Prevot D, Berthet C, Birot AM, Billaud M, Magaud
JP, et al. Interaction of BTG1 and p53-regulated
BTG2 gene products with mCaf1, the murine homolog of a component of
the yeast CCR4 transcriptional regulatory complex. J Biol
Chem 1998; 273: 22563-9.
17. Rouault JP, Rimokh R, Tessa C, Paranhos G, Ffrench M,
Duret L, et al. BTG1, a member of a new family of
anti-proliferative genes. EMBO J 1992; 11: 1663-70.
18. Bogdan JA, Adams-Burton C, Pedicord DL, Sukovich DA,
Benfield PA, Corjay MH, et al. Human carbon catabolite
repressor protein (CCR4)-associative factor 1: cloning,
expression and characterization of its interaction with the B-cell
translocation protein BTG1. Biochem J 1998; 336: 471-81.
|